Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the above-identified application.

Listing of the Claims

Claims 1-14 (cancelled)

Claim 15 (new) A compound of Formula I



Formula I
or a pharmaceutically acceptable salt thereof wherein:

A is structure i;



i

n is 0 or 1;

X is O, S, NH, Nalkyl, NOH, and NOalkyl;

Z is $NHC(=O)R^1$, $NHC(=S)R^1$, $C(=O)NHR^1$, C(=O)N(H)OH, or $NHC(=NCN)R^1$;

R^1 is H, NH_2, NHC_{1-4}alkyl, C_{1-4}alkyl, C_{2-4}alkenyl, $-(CH_2)_mC(=O)C_{1-4}$alkyl, OC_{1-4}alkyl, SC_{1-4}alkyl, $(CH_2)_mC_{3-6}$cycloalkyl, the alkyl optionally being a substituted alkyl;

R^2 and R^3 are independently H or F;

R^4 is H, Cl, F, CH_3, CF_3, NH_2, NO_2 or CN;

R^5 and R^6 are independently H, alkyl, substituted alkyl, -Salkyl, -Oalkyl, alkenyl, substituted alkenyl, hydroxy, aryl or halo;

R^7 is H, alkyl, substituted alkyl, cycloalkyl, C(=O)alkyl, C(=O)substituted alkyl, aryl, alkenyl, or substituted alkenyl; and

each m is independently 0, 1 or 2.

Claim 16 (new) The compound of claim 15, wherein R_7 is alkyl or substituted alkyl.

Claim 17 (new) The compound of claim 15, wherein R_5 is halo.

Claim 18 (new) The compound of claim 15, wherein R_6 is halo.

Claim 19 (new) The compound of Claim 15 which is:

a) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-N-methyl-2-oxo-5-oxazolidinecarboxamide;
b) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinecarboxamide;
c) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinecarboxamide;
d) (5*R*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-N-methyl-2-oxo-5-oxazolidinecarboxamide;
e) N-[[(5*S*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-methyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide; or
f) N-[[(5*S*)-(-)-3-(3,3-difluoro-2,3-dihydro-1-ethyl-2-oxo-1*H*-indol-5-yl)-2-oxo-5-oxazolidinyl]methyl]acetamide.

Claim 20 (new) A method for the treatment of microbial infections in mammals comprising administration of an effective amount of compound of claim 15 to said mammals.

Claim 21 (new) The method of claim 20 wherein said compound is administered to the mammal orally, parenterally, transdermally, or topically.

Claim 22 (new) The method of claim 20 wherein said compound is administered in an amount of from about 0.1 to about 1000 mg of the compound of claim 15.

Claim 23 (new) The method of claim 20 wherein said compound is administered in an amount of from about 0.1 to about 500 mg of the compound of claim 15.

Claim 24 (new) A pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier.